Clinical Trials Logo

HER-2 Negative Breast Cancer clinical trials

View clinical trials related to HER-2 Negative Breast Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03462251 Completed - Breast Cancer Clinical Trials

Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line

RIBBIT
Start date: May 24, 2018
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the efficacy and safety of first-line treatment ribociclib in combination with aromatase inhibitor (AI) or fulvestrant OR capecitabine with bevacizumab OR paclitaxel with / without bevacizumab in patients with HR-positive, HER2-negative advanced breast cancer with visceral metastasis. Half of the patients will receive a combination of ribociclib and AI/fulvestrant while the other half will receive capecitabine + bevacizumab or paclitaxel +/- bevacizumab.